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background: The new 2014 guidelines of the Eighth Joint National Committee (JNC 8) for the treatment of hypertension (HTN) propose 
less restrictive blood pressure (BP) threshold for treatment for old adults aged 60 years or older and for those with diabetes and chronic 
kidney disease (CKD).
Methods: Using data from the Korean National Health and Nutrition Examination Survey of 2008 to 2012 (n=30,697), we estimated 
the number of persons for whom HTN treatment would be recommended (i.e., eligible persons) under the new JNC-8 guideline, as 
compared with JNC-7 guidelines, and extrapolated the results to 35.8 million Koreans adults. Using external validation cohort of the 2003 
National Health Examination (n=116,767), we determined clinical effects of discordant recommendations by the two guidelines on major 
cardiovascular events (cardiovascular death, myocardial infarction, or stroke).
Results: Among 35.8 million adults, as compared with the JNC-7 guidelines, the new JNE-8 guideline would decrease the number of 
adults with treatment-eligible HTN from 10.1 million (28.2%) to 9.3 million (25.9%). This decrease would occur among older adults (≥ 
60 years) (2.6 million to 2.4 million), adults with CKD (0.6 million to 0.5 million), and adults with diabetes (2.2 million to 1.7 million). In 
external validation cohort, as compared to adults without HTN, those who were recommended by the JNC-7 guideline and those who were 
recommended by the JNC-8 guideline had a significantly higher adjusted risk of major cardiovascular events (hazard ratio [HR], 1.75; 95% 
confidence interval [CI], 1.52-2.01 and HR 1.88; 95% CI 1.62-2.19). However, adults who were newly not recommended for HTN treatment 
by the JNC-8 guideline did not have an increased risk (HR 1.16; 95% CI 0.86-1.57).
conclusion:  Compared with the JNC 7 guideline, the new HTN guidelines would decrease the number of adults who would be eligible for 
HTN treatment and would newly recommend avoidance of HTN treatment for those with a relatively lower risk of events.
